secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2023-03-10T23:59:59+00:00
Accession:  0000950170-23-007138
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Frequency Therapeutics discontinues hearing programs, cuts 55% staff after Phase 2b miss, shifts to MS remyelination
--------------------------------------------------------------------------------

- FX-322-208 Phase 2b for hearing loss failed primary endpoint; company ends both FX-322 and FX-345 programs.
- New focus on MS remyelination program; targets clinical development initiation in first half of 2024.
- Restructuring reduces workforce by ~55%, completed by end of April 2023; cash runway extended into 2025.
- Q4 2022 net loss $17.4M; full year net loss $81.6M; cash, equivalents & marketable securities $83.1M at Dec 31, 2022.
- CEO David Lucchino returned from medical leave on March 1, 2023 and resumed all prior duties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000095017023007138/0000950170-23-007138-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000095017023007138/freq-20230310.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-007138

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer